Early phase protein services


Our Applied Protein Services team offers a portfolio of preclinical risk assessment platforms that utilize in silico and in vitro assessment for developability, immunogenicity, stability, humanization, protein engineering and non-GMP protein production. These services utilize our award winning and patented Epibase® T cell epitope screening platform along with our proprietary technology platform for structural protein engineering.

Cambridge by the numbers

3.81
thousand m2 non-GMP site
50
people on site across different research and development functions
90%
of workforce is University educated

Preclinical risk assessment services


Our Cambridge facility is located 50 miles north of London in the UK. 

The Cambridge site has relocated to larger premises and now houses multiple modern preclinical research laboratories with a wide range of high throughput screening equipment. 

Our Applied Protein Services team focuses on a full risk assessment platform for in silico and in vitro services for developability, immunogenicity, stability, antibody humanization, protein engineering and non-GMP mammalian and microbial expression. These services utilize our award winning and patented Epibase® T cell epitope screening platform along with our proprietary platforms for protein risk assessment and engineering and Lonza’s proprietary expression platforms.

Whether you are looking for non-GMP immunogenicity in the case of protein therapeutics, or a strong response to a developing vaccine, our protein experts can help optimize your drug candidate to give you the best chance for clinical success. 

  • Upstream and Downstream non-GMP Protein Expression and Analysis Capabilities
    • Mammalian Cell Culture (CHO based cell lines)
    • E.coli expression
    • Pichia expression
    • Expression quantities from mL to 20L/mg-5g
    • Harvest by Centrifugation and Depth Filtration Train
    • Affinity and non-affinity chromatography
    • Protein Characterization
    • Binding Affinity Analysis
    • Computational Analysis of Protein Sequence and Structure
    • Antibody Humanization and Deimmunisation
    • T cell Immunogenicity risk profiling using proprietary Epibase® platform
    • Protein engineering to de-risk development and manufacture
    • Aggregation prediction using proprietary Sentinel APART® platform
    • Preparation and analysis of human peripheral blood mononuclear cells (PBMCs)
    • T and B cell mediated assessment of immunogenicity (wanted & unwanted) in ex vivo platforms
    • Effector function analysis